DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT Between LUPIN LTD. and SALIX PHARMACEUTICALS, INC. Dated as of September 30, 2009Development, Commercialization and License Agreement • November 9th, 2009 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York
This Development, Commercialization and License Agreement (this “Agreement”) is made and entered into effective as of September 30, 2009 (the “Effective Date”) by and between Lupin Ltd., a corporation organized under the laws of India and having its principal place of business at “B” Wing, Fifth Floor, Bandra Kurla Complex, Mumbai—400 051, India (“Lupin”), and Salix Pharmaceuticals, Inc., a corporation organized under the laws of the State of California in the United States of America and having its principal place of business at 1700 Perimeter Park Drive, Morrisville, North Carolina 27560-8404, U.S.A. (“Salix”). Lupin and Salix are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT between SALIX PHARMACEUTICALS, INC. and LUPIN LTD. Dated as of September 30, 2009Manufacturing Agreement • November 9th, 2009 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • New York
This RIFAXIMIN MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”), dated as of September 30, 2009 (the “Effective Date”), is made by and between Salix Pharmaceuticals, Inc., a California corporation (“Salix”), and Lupin Ltd., a corporation organized under the laws of India (“Lupin”). Salix and Lupin are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
